FDA approval for adalimumab biosimilar Idacio
Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced that the FDA has approved its citrate-free adalimumab biosimilar Idacio for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira(adalimumab)